Provided by Tiger Trade Technology Pte. Ltd.

CSPC PHARMA

8.850
+0.0450.51%
Volume:49.97M
Turnover:442.76M
Market Cap:101.97B
PE:22.26
High:8.945
Open:8.625
Low:8.625
Close:8.805
52wk High:10.720
52wk Low:6.387
Shares:11.52B
HK Float Shares:11.52B
Volume Ratio:0.54
T/O Rate:0.43%
Dividend:0.34
Dividend Rate:3.81%
EPS(LYR):0.398
ROE:20.90%
ROA:10.70%
PB:2.32
PE(LYR):22.26
PS:2.78

Loading ...

CSPC PHARMA: FDA Clears Registrational Trial of Nectin-4 ADC CRB-701 for Second-Line Oropharyngeal Cancer

Bulletin Express
·
Jul 29

CSPC Pharma's CRB-701 (SYS 6002) Gets FDA Nod for Phase 2 Trial in Oropharyngeal Cancer

Stock News
·
Jul 29

CSPC Says FDA Clears Crb-701 Pivotal Trial in Second-line Oropharyngeal Cancer

Reuters
·
Jul 29

CSPC Pharmaceutical - Crb-701 Receives FDA Clearance for Registrational Trial in Second-Line Oropharyngeal Cancer

THOMSON REUTERS
·
Jul 29

CSPC Pharmaceutical Group Stock Rallies 3.2% in Hong Kong, Outperforms Competitors

Dow Jones
·
Jul 29

Movement Alert|CSPC PHARMA Rises 3.06% in Regular Trading, Mid-Term Profit Alert and Multiple Pipeline Catalysts Continue to Ferment

Market Focus
·
Jul 29

Citi Reaffirms Buy Rating on CSPC Pharma, Sets Price Target at HK$11.50

Deep News
·
Jul 29

Citi: CSPC Pharma's (01093) Interim Profit Alert Far Exceeds Expectations, 'Buy' Rating Reaffirmed

Stock News
·
Jul 28

China's CSPC Pharmaceutical Rises on Robust H1 Earnings Forecast

Reuters
·
Jul 28

CSPC Pharma's Depression Drug Meets Primary Endpoint in Phase 3 Trial

MT Newswires Live
·
Jul 28

CSPC Pharma's Sirolimus Drug Application Accepted in China

MT Newswires Live
·
Jul 28

Movement Alert|CSPC PHARMA Rises 3.86% in Regular Trading, Interim Profit Forecast Surges as Antidepressant Drug Phase III Trial Hits Primary Endpoint

Market Focus
·
Jul 28

Hong Kong Stock Market Preview: Disease Prevention 15th Five-Year Plan Issued, SK Hynix Breaches IPO Price on Wall Street

Stock News
·
Jul 28

Cspc Pharmaceutical Says Phase III Trial of Ha1406 Meets Primary Endpoint

Reuters
·
Jul 27

CSPC PHARMA's Injectable Sirolimus (Albumin-Bound) New Drug Application Accepted by China's NMPA

Stock News
·
Jul 27

CSPC Pharma: Ammoxetine (HA1406) Clears Phase III with Statistically Significant Efficacy in Depression

Bulletin Express
·
Jul 27

CSPC Says China NMPA Accepts Sirolimus Albumin-bound Injection Filing, Grants Priority Review

Reuters
·
Jul 27

CSPC Pharmaceutical - Nmpa Accepts New Drug Application for Sirolimus for Injection (Albumin-Bound)

THOMSON REUTERS
·
Jul 27

CSPC Pharmaceutical - Phase Iii Trial of Ha1406 for Depression Meets Primary Endpoint with Statistical Significance

THOMSON REUTERS
·
Jul 27

CSPC PHARMA (01093) Issues Positive Profit Alert, Expects Significant Interim Net Profit Growth to Around RMB 5.9-6.2 Billion

Stock News
·
Jul 27